Drug-Carrying Albumin Film for Blood-Contacting Biomaterials
Drug-Carrying Albumin Film for Blood-Contacting Biomaterials
复制标题
用于血液接触生物材料的载药白蛋白薄膜
DOI：
10.1163/156856209x434665
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
T. Tanabe
中科院分区：
文献类型：
--
作者：
H. Yamazoe;T. Tanabe
表面诱导血栓形成是血液接触医疗器械开发中的主要并发症。血清白蛋白具有与包括药物在内的多种化合物结合的能力，并且细胞和蛋白质都不会吸附到白蛋白包被的表面。白蛋白的这些性质对于改善生物材料表面的血液相容性是有用的。本研究针对临床应用的需要，通过交联药用级重组人血清白蛋白制备了一种水不溶性膜，并在该膜上负载合成的抗血小板药物西洛他唑。所得膜具有天然白蛋白特性，如药物结合能力和抗细胞粘附性。小鼠成纤维细胞L929细胞不粘附在白蛋白膜上，就像它们不粘附在天然白蛋白包被的表面上一样。此外，当将携带西洛他唑的白蛋白膜置于含有Tween-80的PBS中时，西洛他唑的释放持续超过144 h。结果表明，用这种方法制备的白蛋白膜表面涂层，由于其对细胞的非粘附性和其释放西洛他唑，可以赋予生物材料抗血栓形成的表面。
Surface-induced thrombosis is a major complication in the development of blood-contacting medical devices. Serum albumin has the ability to bind to a wide variety of compounds, including drugs, and neither cells nor proteins adsorb to an albumin-coated surface. These properties of albumin are useful for improving the blood compatibility of biomaterial surfaces. In the present study, we prepared a water-insoluble film by cross-linking pharmaceutical grade recombinant human serum albumin aiming to the clinical applications, and loaded the film with a synthetic antiplatelet drug, cilostazol. The resultant film possessed native albumin characteristics such as drug binding ability and resistance to cell adhesion. Mouse fibroblast L929 cells did not adhere on the albumin film, just as they did not adhere on native albumin-coated surfaces. Furthermore, when the albumin film carrying cilostazol was placed in PBS containing Tween-80, the release of cilostazol was sustained over 144 h. The results indicate that the surface coating with thus prepared albumin film can confer the biomaterials with antithrombogenic surface by virtue of its non-adhesiveness to cells and its release of cilostazol.
白蛋白在 C18-烷基衍生的聚氨酯血管移植物上的吸附和保留。
影响因子：
2.4
作者：
Eberhart,RC;Munro,MS;Williams,GB;Kulkarni,PV;ShannonJr,WA;Brink,BE;Fry,WJ
通讯作者：
Fry,WJ